The award-winning international trial, REMAP-CAP, led here in New Zealand by Dr Colin McArthur, Medical Research
Institute of New Zealand (MRINZ) researcher and intensive care specialist at Auckland City Hospital, has provided a
framework that has been able to efficiently evaluate multiple treatment options for patients who are critically ill due
Early in the COVID-19 pandemic, clinicians around the world observed the common occurrence among patients of widespread
blood clots and significant inflammation, which affected multiple organs leading to complications such as lung failure,
heart problems and stroke.
Doctors were unsure whether treating COVID-19 patients with preventative high doses of blood thinners, which would
otherwise be given at low doses to reduce blood clots, would be safe and effective.
The REMAP-CAP platform, an ongoing, adaptive clinical trial, is the largest worldwide study of treatments for critically
ill patients with severe respiratory infections, including COVID-19. The REMAP-CAP randomises patients to receive
combinations of treatments, and now involves more than 7000 COVID-19 patients at more than 300 clinical sites around the
world, including some of the eleven participating ICUs within New Zealand.
Combining with two other trials, the REMAP-CAP assessed the benefit of full doses of blood thinners as preventative
treatment for both critically ill and moderately ill adults hospitalised with COVID-19, compared with a lower dose often
used to prevent blood clots in patients in hospital care.
The studies, published today in the prestigious New England Journal of Medicine, have found that full doses of blood
thinners do not improve outcomes for critically ill patients with COVID-19, and are likely to be harmful. However, for
moderately ill patients, full-dose blood-thinning medication is beneficial.
With large numbers of COVID-19 patients requiring hospitalisation, this treatment is expected to improve outcomes, and
reduce the pressure in intensive care units around the world.
Dr Colin McArthur says the findings are significant. “Since early in the pandemic doctors have been uncertain how to
best provide preventative therapy for blood clotting complications, an important contributor to mortality from COVID-19.
These study findings now make it clear that higher doses of blood thinners are beneficial for patients with COVID-19
requiring hospitalisation, but are not beneficial when patients require intensive care-level treatment. Along with other
treatments evaluated by the REMAP-CAP study, these results further build our knowledge of how to best treat this
The MRINZ has played a crucial senior role in the establishment and running of the REMAP-CAP study through the
leadership of Dr Colin McArthur. Adding to New Zealand’s contribution to the ongoing success of the trial, Spiral Web
Solutions, based in Wellington, provide most of the database services for the global REMAP-CAP platform.
Professor Richard Beasley, director of MRINZ says, “These remarkable study findings will save lives worldwide. It’s a
genuinely great achievement that New Zealand has such a strong international leadership role in the REMAP-CAP clinical
trials programme that has led to this evidence, thanks in large part to the support of the Health Research Council and
the Ministry of Health.”
“The dedicated work of Dr McArthur and his team here in New Zealand has contributed to an immense collaborative effort
involving patients, clinicians, and research staff around the world, enabling us to rapidly learn how best to treat
COVID-19. It’s an extremely complicated disease, and we’re discovering so much more about how to best treat patients
with COVID-19 through these studies,” says Professor Beasley.